{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:47:06Z","timestamp":1759938426162},"reference-count":12,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,2,13]],"date-time":"2008-02-13T00:00:00Z","timestamp":1202860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2008,5]]},"abstract":" WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p>\u2022\u2003Insufficient drug adherence is an important reason for inadequate blood pressure control.<\/jats:p>\u2022\u2003Currently, methods that measure drug adherence objectively are lacking. Objective methods are needed to help improve blood pressure control and outcome in hypertensive patients.<\/jats:p> WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p>\u2022\u2003Potassium bromide added to antihypertensive drugs can be used to monitor drug adherence in individual patients.<\/jats:p>\u2022\u2003However, although this method is objective, it is rather time\u2010, cost\u2010 and work\u2010consuming.<\/jats:p>AIMS<\/jats:bold> Adherence to antihypertensive medication is essential for adequate long\u2010term control of blood pressure (BP). This study investigated different methods of measuring adherence in hypertensive patients.<\/jats:p>METHODS<\/jats:bold> Patients were included if BP was insufficiently controlled on monotherapy. After a placebo period patients were treated with trandolapril 2\u2003mg\/verapamil SR 180\u2003mg (TV). BP was determined using a mercury sphygmomanometer and ambulatory BP monitoring. Adherence was measured by capsule counting, electronic registration of pill\u2010box openings and by measuring serum bromide concentrations. Potassium bromide was added to each TV capsule.<\/jats:p>RESULTS<\/jats:bold> Thirty patients participated in the study. Treatment with TV significantly lowered office BP and ambulatory BP.<\/jats:p>Results for electronic monitoring and adherence based on bromide measurements were comparable. Adherence was slightly higher when assessed by capsule counting.<\/jats:p>CONCLUSIONS<\/jats:bold> Measuring serum bromide concentrations may be suitable for assessment of adherence to drug therapy giving comparable results to electronic monitoring. Using capsule counting, electronic monitoring and measurement of bromide concentrations, nonadherent patients were identified.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2007.03068.x","type":"journal-article","created":{"date-parts":[[2008,2,13]],"date-time":"2008-02-13T15:24:30Z","timestamp":1202916270000},"page":"733-736","source":"Crossref","is-referenced-by-count":6,"title":["Bromide as marker for drug adherence in hypertensive patients"],"prefix":"10.1111","volume":"65","author":[{"given":"Richard L.","family":"Braam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stan H. M.","family":"Van Uum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques W. M.","family":"Lenders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo","family":"Thien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,2,13]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0103-5"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198601000-00007"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7117.2000.tb00211.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03500210079036"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199427030-00004"},{"issue":"2","key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/00004872-200305002-00007","article-title":"Monitoring compliance in resistant hypertension: an important step in patient management","volume":"21","author":"Burnier M","year":"2003","journal-title":"J Hypertens"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-35355"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1970112228"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.121"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/8.suppl_I.31"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03139.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2007.03068.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2007.03068.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T03:22:49Z","timestamp":1697426569000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2007.03068.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,13]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1111\/j.1365-2125.2007.03068.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2007.03068.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,13]]}}}